Summary: Establishment Labs Holdings Inc, a global medical technology company specializing in women’s health, announces the first U.S. breast augmentations using Motiva Implants.

Key Takeaways

  1. Establishment Labs performed the first U.S. breast augmentations using FDA-approved Motiva Implants.
  2. The FDA approval has increased demand, leading the company to expand its sales team.
  3. Motiva Implants are designed to improve biocompatibility, reduce inflammation, and mimic natural movement.

—————————————————————————————————————————————

Establishment Labs Holdings Inc, a global medical technology company specializing in women’s health, announces the first U.S. breast augmentations using Motiva Implants.

“With the FDA approval last week, we are experiencing high demand for Motiva Implants—both from surgeons and patients,” says Juan José Chacón-Quirós, founder and CEO of Establishment Labs. “The FDA approval came as we were attending the annual conference of the American Society of Plastic Surgeons. The response was overwhelming, and our team has already talked to more than 400 plastic surgeons post announcement. Since approval, we have already doubled our team to 25 sales reps across the United States, and our story of real innovation, backed by science and data, is resonating strongly. Everything we are seeing suggests that we can be the implant of choice in the United States.”

Milestone for Motiva SmoothSilk Breast Implants

M. Bradley Calobrace, MD, Kentucky-based board-certified plastic surgeon, and Caroline A. Glicksman, MD, New Jersey-based board-certified plastic surgeon, performed the first surgeries following the U.S. FDA approval of Motiva SmoothSilk Ergonomix and Motiva SmoothSilk Round breast implants in primary and revision breast augmentation.

“I have many patients that have been waiting a long time for Motiva approval, in some cases, for years,” says Calobrace. “I was delighted to perform one of the first Motiva breast augmentations in the United States. The innovation in these devices not only enhances aesthetics outcomes, but also significantly lowers the rates of the complications we see with other devices. Motiva implants are a game-changer.”

Enhanced Biocompatibility and Reduced Inflammation

Motiva Implants feature a SmoothSilk surface for enhanced biocompatibility and reduced inflammation. The Ergonomix implants mimic natural breast movement, changing shape based on body position, while the SmoothSilk Round implants offer fullness and softness in all positions.

“The plastic surgery community has waited over a decade for a truly new option,” adds Glicksman, medical director of the Motiva U.S. IDE Study. “Now, we can confidently offer implants with low complication rates and high patient satisfaction.”